WORLD EMERGENCY MEDICINE SOCIETIES & RELATED

Search

Content:

Saturday, October 24, 2015

Andexanet alfa: FXa Inhibitor Antidote

"Potential first-in-class recombinant, modified Factor Xa molecule that is being developed as an antidote for patients receiving a Factor Xa inhibitor who suffer a major bleeding episode or who may require emergency surgery...
Currently being evaluated in two randomized, double-blind, placebo-controlled ANNEXA™ (Andexanet Alfa a Novel Antidote to the Anticoagulant Effects of fXA Inhibitors) Phase 3 studies that are studying the safety and efficacy of andexanet alfa in reversing anticoagulation induced by Eliquis® (apixaban) or XARELTO® (rivaroxaban) rapidly after an IV bolus and sustaining that effect through a continuous infusion."
https://www.portola.com/clinical-development/andexanet-alfa-prt4445-fxa-inhibitor-antidote/